Compare FMBH & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMBH | CTMX |
|---|---|---|
| Founded | 1865 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 951.4M | 977.1M |
| IPO Year | 1995 | 2015 |
| Metric | FMBH | CTMX |
|---|---|---|
| Price | $41.19 | $4.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $43.40 | $12.10 |
| AVG Volume (30 Days) | 113.9K | ★ 10.1M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | ★ 16.06 | N/A |
| EPS | ★ 3.83 | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | $9.38 | N/A |
| Revenue Next Year | $6.55 | $27.22 |
| P/E Ratio | ★ $10.77 | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.58 | $0.40 |
| 52 Week High | $44.85 | $8.21 |
| Indicator | FMBH | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 54.29 | 48.64 |
| Support Level | $40.83 | $3.55 |
| Resistance Level | $41.25 | $6.20 |
| Average True Range (ATR) | 0.86 | 0.61 |
| MACD | 0.21 | -0.02 |
| Stochastic Oscillator | 91.28 | 15.74 |
First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The Company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.